Astria Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Astria Therapeutics highlights clinical advancements in navenibart for hereditary angioedema and STAR-0310 for atopic dermatitis in its 2024 annual report, alongside financial details and future outlook.
Astria Therapeutics, a biopharmaceutical company, released its full year 2023 results, highlighting progress in its clinical development programs for allergic and immunological diseases.